TargetBeta
SCN10A
sodium voltage-gated channel alpha subunit 10 · also Nav1.8, hPN3, SNS, PN3 · Sodium voltage-gated channel alpha subunits
13 programs in company-led studies act on SCN10A, from 12 companies: 4 in phase 3, 8 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (11 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Lidocainerule | Keenova Therapeutics | phase 4 | 632 running | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A | ChEMBL |
| Riluzolerule | Sanofi | phase 4 | 62 running | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A | ChEMBL |
| Carbamazepinerule | GRIN Therapeutics | phase 4 | 211 running | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A | ChEMBL |
| chloroprocainerule | Sintetica | phase 4 | 81 running | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A | ChEMBL |
| Carticainerule | Laboratoires Thea | phase 4 | 11 running | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A | ChEMBL |
| Lamotriginerule | GlaxoSmithKline | phase 4 | 610 running | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A | ChEMBL |
| Dronedaronerule | Sanofi | phase 4 | 180 running | CACNA1C, CACNA1D, CACNA1F, CACNA1S, HCN4, KCNJ2, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A | ChEMBL |
| Prilocainerule | Haisco Pharmaceutical Group | phase 4 | 20 running | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A | ChEMBL |
| Ropivacainerule | PainReform | phase 3 | 174 running | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A | ChEMBL |
| HRS-2129 | Jiangsu HengRui Medicine | phase 3 | 72 running | – | the company's pipeline |
| Phenytoinrule | Viatris | phase 3 | 101 running | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A | ChEMBL |
| rufinamiderule | Eisai | phase 3 | 70 running | SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A | ChEMBL |
| LY4515100 | Eli Lilly | phase 2 | 33 running | – | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Epilepsy, 4 programs
- Pain, 3 programs
- Bipolar Disorder, 2 programs
- Hepatitis C, 2 programs
- Hernia, Inguinal, 2 programs
- Neuralgia, 2 programs
- Neuralgia, Postherpetic, 2 programs
- Osteoarthritis, Knee, 2 programs
- Pain, Postoperative, 2 programs
- Acute Pain, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026LY4515100 · Eli Lilly · phase 2 · NCT07511816
- Dec 2027Carticaine · Laboratoires Thea · phase 4 · NCT07838129
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.